Tags: Drug.
Ofatumumab (trade name Arzerra also known as HuMax-CD20) is a humanized monoclonal antibody (for the CD20 protein) which appears to inhibit early-stage B lymphocyte activation. It is FDA approved for treating chronic lymphocytic leukemia that is refractory to fludarabine and alemtuzumab (Campath) and has also shown potential in treating Follicular non-Hodgkin’s lymphoma Diffuse large B cell lymphoma rheumatoid arthritis and relapsing remitting multiple sclerosis.